0105 : Evaluation of management of heart failure and sleep apnea syndrome in a cardiac intensive care unit  by Houssany, Sonia & Roche, Nicolas-Charles
© Elsevier Masson SAS. All rights reserved.
 
176 Archives of Cardiovascular Diseases Supplements (2015) 7, 175-177
Conclusion: The effects of fasting during Ramadan on stable patients with
chronic heart failure are minimal. The majority of patients with stable cardiac
disease can fast during Ramadan without significant detrimental effects.
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Background: Sleep apnea syndrome (SAS) is seen in approximately 40%
of patients with congestive heart failure. SAS is also associated with an
increased mortality in patients with systolic heart failure. The aim of this work
was to evaluate the screening for SAS in patients hospitalized for acute
congestive heart failure in a cardiac intensive care unit.
Method: We performed a single-center retrospective study of patients hos-
pitalized for congestive heart failure with altered left ventricular ejection frac-
tion (lvef) ≤45% from june to december 2013. We assessed the screening for
sleep apnea syndrom using Epworth sleepiness scale.
Results: We included 51 patients. Mean values were for age 76 y. o, men
54%, body mass index 27kg/m², lvef 32%, diabetese 34%, hypertension 40%,
NYHA III 38% and NYHA IV 50%. Only 14% (7) of patients were screened
for SAS using the Epworth scale. All of them benefited a polysomnography at
less one month after discharge. 6 of them (85%) were diagnosed with SAS.
Conclusion: Although Epworth scale is a usefull and easy tool, Apnea
syndrom remains underdiagnosed. Because of its high prevalence, poor out-
come, and the beneficial effects of treatment, cardiologist should be more
aware of SAS
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Breast radiotherapy (RT) techniques used until the 1990s were respon-
sible for increased mortality due to long term cardiac complications. Since
the 2000s, improved techniques of RT have appeared leading to different
dose distributions to organ at risks such as heart. But up to now, little is
known on their cardiac toxicity. The aim of the REBECCA study is to eval-
uate whether helical tomotherapy (HT) induces cardiac toxicity that could be
detected in the first two years after treatment based on analysis of sub-
clinical functional and anatomical cardiac lesions at myocardial and coro-
nary levels and evolution of circulating biomarkers. REBECCA study is a
prospective cohort study that will include 120 women treated with adjuvant
HT for breast cancer at the Institut Universitaire du Cancer Toulouse-Onco-
pole (IUCT), and followed up for 2 years after RT. Women aged 40 to
70 years, surgically treated at IUCT for breast cancer and for whom adjuvant
RT with HT is indicated, without chemotherapy will be eligible for the
study. Follow-up will include measures of a panel circulating biomarkers,
coronary plaque index based on Coronary computed tomography angio-
graphy and myocardial strain based on 2D-speckle tracking echocardiog-
raphy. Absorbed doses will be evaluated for the whole heart and for each
different parts of heart, in particular coronary arteries. Analysis will focus
on dose-response relationship between subclinical cardiac lesions, bio-
markers, and different organ absorbed doses. Furthermore, this study aims
to create a bio-bank of plasma and blood of this cohort for future investiga-
tions. This clinical research study is a novel approach to early detect cardio-
toxicity of current breast RT, combining anatomical and functional heart
consequences based on cardiac imaging, a panel of circulating biomarkers
and a detailed heart dosimetry. With this approach, REBECCA aims to
improve understanding of the mechanisms and circumstances that underlie
the development of potential heart side effects and sequelaes.
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Purpose: Pulmonary hypertension (PH) is a predictor of mortality and
morbidity in patients with chronic heart failure (HF) but it is poorly described
in our population. We sought to study, the prevalence, determinants, and prog-
nostic significance of PH in a large representative population with HF.
Methods: We retrospectively studied 1613 patients with HF. Systolic pul-
monary artery pressure PASP was determined by echocardiography, PH was
defined as PAPS> 50 mmHg.
Results: The proportion of patients with PASP>50mm Hg was:
12,15%(196/1613),with an average age of 69 years, there was 40,30% women
and 59,70% men, 96,43% of patients had low LVEF( left ventricular ejection
fraction) and only 1,02% had preserved LVEF. The ischemic etiology of HF
was predominant (17,86%).Most patients were receiving diuretics (66,33%),
beta-blockers (58,16%) and ACE inhibitor (86,22%), whereas 55, 10% were
on Spironolactone. The etiology of PH was mostly due to the left heart dis-
ease, while 1.02% was due to primary HP and 2.04% patient had COPD
(Chronic obstructive pulmonary disease). Patients with PH had a rate of
6.06% of AHFD (acute heart failure decompensation) occurrence. we note that
patients with both PH and RV dysfunction had a greater risk of AHFD
(14.28%).
Conclusion: PH is common in HF patients, associated with worse LV
function and provide incremental prognostic informations. The combination of
PH and RV dysfunction is particularly ominous. Thus, the estimation of PASP
should be considered in the standard assessment of ambulatory HF patients
and we must study it as a therapeutic way in this population
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Background: The long-term cardiac prognosis of adults with mitochon-
drial diseases is unknown.
Methods and Results: Between January 2000 and May 2014, we retro-
spectively included in this study 260 consecutive patients (60% women)
≥18 years of age, [interquartile range (IQR) = 31 to 54], with genetically
proven mitochondrial diseases, including 109 with mtDNA single large-scale
deletions, 64 with the m.3243A>G mutation in MT-TL1, 51 with other
